Awarded Trial: BPN-5
Secondary Drug Intervention
Duration of Study Period for Each Subject
Forty six patients with bipolar disorder, who had also experienced significant weight gain (>10 pounds since intiation of current psychotropic regimen and a BMI > 30 kg/m2) were randomized to receive adjunctive topiramate or sibutramine for 26 weeks. Subjects receiving topiramate discontinued more often than those receiving sibutramine, but patients receiving topiramate experienced improvements in YMRS and IDS-C scores. Both drugs were associated with significant weight loss.
McElroy SL, Frye MA, Altshuler LL, Suppes T, Hellemann G, Black D, Mintz J, Kupka R, Nolen W, Leverich GS, Denicoff KD, Post RM, Keck PE Jr. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorder. Bipolar Disorders 9:426-434, 2007.
University of Cincinnati College of Medicine
231 Albert Sabin Way
City or Town
State or Province
Zip or Postal Code